Project Details
Description
A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients
| Status | Finished |
|---|---|
| Effective start/end date | 11/15/15 → 4/1/19 |
Funding
- ASTRAZENECA
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.